VISIT US IN CHICAGO JUNE 2-4 AT BOOTH 2073!

Dr. Venook Discusses the Approval of Ramucirumab Plus Paclitaxel

Alan P. Venook, MD,
Published: Friday, Nov 07, 2014

Alan P. Venook, MD, professor, Department of Medicine (Hematology/Oncology), University of California, San Francisco, discusses the approval of ramucirumab plus paclitaxel for gastric cancer.

Venook says the approval is a benefit for all oncologists. While ramucirumab was already being combined with other agents, oncologists now know its benefit when combined with paclitaxel.

Ramucirumab’s expanded approval was based on two studies- one evaluating the drug as monotherapy and one evaluating the drug in combination with a taxane, Venook says.

Venook also says that ramucirumab is being evaluated in other disease.

<<< View more from the 2014 Chemotherapy Foundation Symposium

Alan P. Venook, MD, professor, Department of Medicine (Hematology/Oncology), University of California, San Francisco, discusses the approval of ramucirumab plus paclitaxel for gastric cancer.

Venook says the approval is a benefit for all oncologists. While ramucirumab was already being combined with other agents, oncologists now know its benefit when combined with paclitaxel.

Ramucirumab’s expanded approval was based on two studies- one evaluating the drug as monotherapy and one evaluating the drug in combination with a taxane, Venook says.

Venook also says that ramucirumab is being evaluated in other disease.

<<< View more from the 2014 Chemotherapy Foundation Symposium


View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
34th Annual Miami Breast Cancer Conference® Clinical Case Vignette Series™May 25, 20182.0
Community Practice Connections™: CDK4/6 Inhibitors With the Experts: The Role of Emerging Agents for the Management of Metastatic Breast CancerMay 30, 20182.0
Publication Bottom Border
Border Publication
x